Becker's Healthcare August 16, 2024
Lykos Therapeutics, the manufacturer of midomafetamine (MDMA), which had been tested for PTSD treatment, will reduce its workforce by 75% after the FDA rejected the company’s new drug application.
The remaining workforce, led by senior medical adviser David Hough, MD, will focus on clinical development and FDA engagement, according to an Aug. 15 news...